



Lantheus Second Quarter 2025 Results

August 6, 2025

FIND. FIGHT. FOLLOW.™

© 2025 Lantheus. All rights reserved.



Agenda

Highlights and Business Update

Operational and Strategic Update

Financial Update

Closing Remarks

Q&A

SPEAKERS



Brian Markison
CEO



Paul Blanchfield
President



Bob Marshall
CFO and Treasurer



Mark Kinarney
Vice President,
Investor Relations

Safe Harbor Statements

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as "advance," "aim," "believes," "building," "continue," "could," "creating," "driving," "evolving," "expect," "guidance," "intend," "maintain," "may," "on track," "plan," "position," "potential," "predict," "should," "target," "will," "would" and other similar terms. Such forward-looking statements include our guidance for the fiscal year 2025, our plans to expand our portfolio of late-stage assets and high potential early-stage candidates, our acquisitions of Evergreen Theragnostics Inc. ("Evergreen") and Life Molecular Imaging Ltd. ("Life Molecular"), and our plans to divest our SPECT business to Illuminated Holdings, Inc., the parent company of SHINE Technologies, LLC ("SHINE"), and are based upon current plans, estimates and expectations that are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements include: (i) continued market expansion and penetration for our established commercial products, particularly PYLARIFY and DEFINITY, in a competitive environment and our ability to clinically and commercially differentiate our products; (ii) our ability to have third parties manufacture our products and our ability to manufacture DEFINITY in our in-house manufacturing facility, in amounts and at the times needed; (iii) the availability of raw materials, key components, and equipment, either used in the production of our products and product candidates, or in the use by healthcare professionals ("HCPs") of our products and product candidates, including, but not limited to positron emission tomography ("PET") scanners for PYLARIFY, MK-6240 and NAV-4694; (iv) our ability to satisfy our obligations under our existing clinical development partnerships using MK-6240 or NAV-4694 as a research tool and under the license agreements through which we have rights to MK-6240 and NAV-4694, and to further develop and commercialize MK-6240 and NAV-4694 as approved products, including the timing for any potential regulatory submissions for these investigational assets; (v) our ability to successfully integrate acquisitions, including of Life Molecular and Evergreen, including the potential for unforeseen expenses related to integration activities, the accuracy of our financial models, the potential for unforeseen liabilities within those businesses, the ability to integrate disparate information technology systems, retain key talent and create a merged corporate culture that successfully realizes the full potential of the combined organization; (vi) our ability to obtain U.S. Food and Drug Administration ("FDA") approval for our new F-18 PSMA PET product candidate, to complete the technology transfer across our PET manufacturing facilities network for such new product candidate, and to obtain adequate coding, coverage and payment, including transitional pass-through payment status, for such new product candidate; (vii) our ability to complete the sale of our single-photon emission computerized tomography ("SPECT") business to SHINE on the proposed terms or on the anticipated timeline, or at all, including risks and uncertainties related to securing the necessary regulatory approvals and satisfaction of other closing conditions to consummate the transaction, unforeseen expenses related to the divestiture, and failure to realize the expected benefits of the transaction; (viii) our ability to obtain FDA approval for LNTH-2501, our investigational kit for the preparation of Gallium-68 DOTATOC, which may be used in conjunction with a PET scan to stage and localize gastroenteropancreatic neuroendocrine tumors in adults and children, and approval for PNT2003, and to be successful in the patent litigation associated with PNT2003; (ix) the cost, efforts and timing for clinical development, regulatory approval, adequate coding, coverage and payment and successful commercialization of our product candidates and new clinical applications and territories for our products, in each case, that we or our strategic partners may undertake; (x) our ability to identify opportunities to collaborate with strategic partners and to acquire or in-license additional diagnostic and therapeutic product opportunities in oncology, neurology and other strategic areas and continue to grow and advance our pipeline of products; and (xi) the risk and uncertainties discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q).

All trademarks, logos and service marks used in this presentation are the property of their respective owners.

Non-GAAP Financial Measures

The Company uses non-GAAP financial measures, such as adjusted net income and its line components; adjusted net income per share - fully diluted; adjusted operating income and free cash flow. The Company's management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company's operations, period over period. However, these measures may exclude items that may be highly variable, difficult to predict and of a size that could have a substantial impact on the Company's reported results of operations for a particular period. Management uses these and other non-GAAP measures internally for evaluation of the performance of the business, including the evaluation of results relative to employee performance compensation targets. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

Agenda

Highlights and Business Update

Operational and Strategic Update

Financial Update

Closing Remarks

Q&A

SPEAKERS



Brian Markison
CEO



Paul Blanchfield
President



Bob Marshall
CFO and Treasurer



Mark Kinarney
Vice President,
Investor Relations

Lantheus, the Leading Radiopharmaceutical-Focused Company

2Q 2025 Results

Revenues: \$378M (-4.1%)

Adj EPS¹: \$1.57 (-12.8%)



SALES: \$251M



SALES: \$84M

>3.5M 

Patient lives impacted
in 1H 2025²

Near- and Long-Term Focus

▶ Drive
commercial
execution

▶ Strengthen
radiodiagnostic &
radiotherapeutic
capabilities

▶ Expand
commercial
portfolio &
pipeline

▶ Enhance
long-term
growth
potential

LAYING THE FOUNDATION for the next chapter of our business

ACQUISITIONS



4 KEY PRODUCT
LAUNCHES
anticipated in the
next 18 months³

MK-6240 Next-generation tau imaging agent for Alzheimer's disease

OCTEVY Ga-68 PET imaging agent for neuroendocrine tumors

PNT2003 Radiotherapeutic for neuroendocrine tumors

NEW PSMA PET NEW formulation of F-18 PET imaging agent

Agenda

Highlights and Business Update

Operational and Strategic Update

Financial Update

Closing Remarks

Q&A

SPEAKERS



Brian Markison
CEO



Paul Blanchfield
President



Bob Marshall
CFO and Treasurer



Mark Kinarney
Vice President,
Investor Relations

Lantheus is Committed to Maintaining Market Leadership



\$251M
2Q 2025 Sales | **-8.3% YoY**

- ✓ Clear and compelling clinical differentiation
- ✓ Disciplined pricing strategy
- ✓ Prioritize exceptional customer service & long-term partnerships with the Nuclear Medicine community

EXPANDING PORTFOLIO



Globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer's disease

NEW F-18, PSMA PET formulation

March 6, 2026
PDUFA date

Enhance
production
efficiency

Increase
batch sizes

Improve
patient and
customer access

Support
long-term
PSMA PET growth



Growing interest in our pipeline across the Nuclear Medicine community

ALZHEIMER'S IMAGING

**MK-6240 &
LNTH-2620**
F-18 Tau imaging

NAV-4694
F-18 β -Amyloid
imaging

PNT2003
Radiotherapeutic

OCTEVY
Ga-68 PET imaging

NEUROENDOCRINE TUMORS



Focused on PYLARIFY differentiation and a growing pipeline to support leadership and return to growth



#1 Utilized Ultrasound Enhancing Agent¹

2Q 2025

\$83.9M

2Q 2025 Net Sales

+7.5% Growth

2Q 2025 Year-over-Year

DEFINITY's long-term success remains driven by

- ✓ Its proven clinical and commercial value
- ✓ Long-standing track record of clinical application
- ✓ Our ongoing operational excellence²

1. DRG Real World Data (RWD) report; 2. Internal analyses and data on file.

Agenda

Highlights and Business Update

Operational and Strategic Update

Financial Update

Closing Remarks

Q&A

SPEAKERS



Brian Markison
CEO



Paul Blanchfield
President



Bob Marshall
CFO and Treasurer



Mark Kinarney
Vice President,
Investor Relations

2Q 2025 Financial Results¹

	2Q25	vs 2Q24	
Net Revenues	\$378.0 Million	-4.1%	<ul style="list-style-type: none">• Radiopharmaceutical Oncology: \$250.6M in sales, -8.3% YoY driven by volume increase of 4% sequentially offset by higher competitive dynamics in net price environment• Precision Diagnostic: \$115.8M in sales, +3.3% YoY driven by sales of DEFINITY +7.5% YoY• Strategic Partnerships: \$11.6 million in sales, +32.8% YoY with contributions from MK-6240 and Evergreen CDMO business
GAAP EPS	\$1.12	+27.3%	<ul style="list-style-type: none">• Non-recurring expenses tied to closing and integrating announced acquisitions, divestiture and other strategic collaborations totaled \$32.9M offset in part by unrealized gain on equity investments of \$14.5M
Non-GAAP EPS	\$1.57	-12.8%	<ul style="list-style-type: none">• GAAP EPS: Increase driven by one-time gains and lower impact from non-cash expenses, offsetting core business headwinds• Non-GAAP EPS: Decrease mainly due to unfavorable pricing impacts and increased R&D

**Focus on Driving Commercial Execution and Strengthening Position
for Long-Term Value Creation, Growth and Radiopharmaceutical Leadership**

1. See slide 21 for a reconciliation of GAAP to non-GAAP financials; certain amounts may be subject to rounding.

Strong Capital Resources Provide Financial Flexibility¹


Cash Flow Summary

USD Millions

Three Months Ending June 30

	2024	2025
Cash provided by operations	\$84.7	\$87.1
Cash used in investing	(\$45.1)	(\$232.5)
Cash provided by (used in) financing	\$0.1	(\$98.4)

Free Cash Flow²



Resources

(2Q 2025)




Board authorization of new \$400M Stock Repurchase Program underscores strong confidence in strategic direction

1. Certain amounts may be subject to rounding; 2. See slide 24 for reconciliations of GAAP to non-GAAP financials; 3. Cash, cash equivalents and restricted cash at the end of the period was \$697.3M, after repurchasing \$100.0M of shares during the quarter.

Updated FY 2025 Corporate Financial Guidance¹

Guidance Issued August 6, 2025

The Updated Interim Corporate Financial Guidance for the Full Year 2025 is as Follows:

 <div>FY 2025</div>	Prior Revenue	\$1.550B – \$1.585B
	Current Revenue	\$1.475B – \$1.51B
	Prior Adjusted Fully Diluted EPS ²	\$6.60 – \$6.70
	Current Adjusted Fully Diluted EPS²	\$5.50 – \$5.70

1. On a forward-looking basis, the Company does not provide GAAP income per common share guidance or a reconciliation of GAAP income per common share to adjusted fully diluted EPS because the Company is unable to predict with reasonable certainty business development and acquisition-related expenses, purchase accounting fair value adjustments and any one-time, non-recurring charges. These items are uncertain, depend on various factors, and could be material to results computed in accordance with GAAP. As a result, it is the Company's view that a quantitative reconciliation of adjusted fully diluted EPS on a forward-looking basis is not available without unreasonable effort.

2. FY 2025 guidance assumes fully diluted, weighted average shares outstanding of approximately 70.5M YTD, and depreciation and amortization of approximately \$55M excluding the impacts of LMI intangible assets.

Agenda

Highlights and Business Update

Operational and Strategic Update

Financial Update

Closing Remarks

Q&A

SPEAKERS



Brian Markison
CEO



Paul Blanchfield
President



Bob Marshall
CFO and Treasurer



Mark Kinarney
Vice President,
Investor Relations

Lantheus, the Leading Radiopharmaceutical-Focused Company

2Q 2025

Key Takeaways

Near- and Long-Term Focus

- **Drive** commercial execution
- **Strengthen** radiodiagnostic & radiotherapeutic capabilities
- **Expand** commercial portfolio & pipeline
- **Enhance** long-term growth potential

LAYING THE FOUNDATION

drive future growth and long-term shareholder value



Acquisitions



Diversifying Revenue



Globally approved F-18 PET imaging agent for Alzheimer's disease (AD)



Four key product launches

anticipated in the next 18 months¹

MK-6240

Late-stage Tau AD imaging agent

PNT2003

Radiotherapeutic for neuroendocrine tumors

OCTEVY

Ga-68 PET imaging agent for neuroendocrine tumors

**NEW
PSMA PET**

NEW Formulation of F-18 PET imaging agent

Advancing our Purpose to


➤ **FIND, FIGHT and FOLLOW** Disease to Deliver Better Patient Outcomes

1. Subject to submission and/or receipt of FDA approval.

Appendix

Innovation that Makes an Impact

Expanding Pipeline of Radiopharmaceuticals



1. Also known as ⁶⁸Ga-RM2 2. Also known as ¹⁷⁷Lu-RM2. 3. Collaboration with POINT Biopharma Global Inc.

Condensed Consolidated Statement of Operations – 2Q 2025

(in thousands, except per share data - unaudited)

	2Q 2025		2Q 2024		% Increase/ (Decrease)
	Amount	% Revenue	Amount	% Revenue	
Revenues	\$ 378,045	100.0	\$ 394,091	100.0	(4.1)
Cost of goods sold	137,034	36.2	138,317	35.1	(0.9)
Gross profit	241,011	63.8	255,774	64.9	(5.8)
Operating expenses					
Sales and marketing	41,041	10.9	45,035	11.4	(8.9)
General and administrative	66,515	17.6	47,409	12.0	40.3
Research and development	45,489	12.0	60,601	15.4	(24.9)
Total operating expenses	153,045	40.5	153,045	38.8	-
Operating income	87,966	23.3	102,729	26.1	(14.4)
Interest expense	4,917	1.3	4,862	1.2	1.1
Investment in equity securities - unrealized (gain) loss	(14,573)	(3.9)	22,537	5.7	(164.7)
Other income	(6,895)	(1.8)	(9,044)	(2.3)	(23.8)
Income before income taxes	104,517	27.6	84,374	21.4	23.9
Income tax expense	25,762	6.8	22,301	5.7	15.5
Net income	\$ 78,755	20.8	\$ 62,073	15.8	26.9
Net income per common share - diluted	\$ 1.12		\$ 0.88		
Weighted-average common shares outstanding - diluted	70,312		70,601		

As Adjusted Condensed Consolidated Statement of Operations – 2Q 2025

(in thousands, except per share data - unaudited)

	2Q 2025		2Q 2024		% Increase/ (Decrease)
	Amount	% Revenue	Amount	% Revenue	
Revenues	\$ 378,045	100.0	\$ 394,091	100.0	(4.1)
Cost of goods sold	122,583	32.4	124,646	31.6	(1.7)
Gross profit	255,462	67.6	269,445	68.4	(5.2)
Operating expenses					
Sales and marketing	36,410	9.6	41,959	10.6	(13.2)
General and administrative	37,389	9.9	36,725	9.3	1.8
Research and development	29,091	7.7	19,645	5.0	48.1
Total operating expenses	102,890	27.2	98,329	25.0	4.6
Operating income	152,572	40.4	171,116	43.4	(10.8)
Interest expense	4,917	1.3	4,862	1.2	1.1
Investment in equity securities - unrealized gain	(42)	(0.0)	-	-	-
Other income	(6,895)	(1.8)	(9,044)	(2.3)	(23.8)
Income before income taxes	154,592	40.9	175,298	44.5	(11.8)
Income tax expense	43,968	11.6	48,459	12.3	(9.3)
Net income	\$ 110,624	29.3	\$ 126,839	32.2	(12.8)
Net income per common share - diluted	\$ 1.57		\$ 1.80		
Weighted-average common shares outstanding - diluted	70,312		70,601		

Condensed Consolidated Statement of Operations – 2Q 2025

(in thousands, except per share data)

	2025		2024		% Increase/ (Decrease)
	Amount	% Revenue	Amount	% Revenue	
Revenues	\$ 750,809	100.0	\$ 764,066	100.0	(1.7)
Cost of goods sold	272,098	36.2	266,446	34.9	2.1
Gross profit	478,711	63.8	497,620	65.1	(3.8)
Operating expenses					
Sales and marketing	83,544	11.1	90,581	11.9	(7.8)
General and administrative	123,331	16.4	95,304	12.5	29.4
Research and development	81,803	10.9	108,625	14.2	(24.7)
Total operating expenses	288,678	38.4	294,510	38.5	(2.0)
Gain on sale of assets	-	-	6,254	0.8	(100.0)
Operating income	190,033	25.3	209,364	27.4	(9.2)
Interest expense	9,721	1.3	9,721	1.3	-
Investment in equity securities - unrealized loss (gain)	289	0.0	(38,167)	(5.0)	(100.8)
Other income	(21,023)	(2.8)	(17,832)	(2.3)	17.9
Income before income taxes	201,046	26.8	255,642	33.5	(21.4)
Income tax expense	49,346	6.6	62,503	8.2	(21.1)
Net income	\$ 151,700	20.2	\$ 193,139	25.3	(21.5)
Net income per common share - diluted	\$ 2.14		\$ 2.74		
Weighted-average common shares outstanding - diluted	70,896		70,364		

As Adjusted Condensed Consolidated Statement of Operations – 2Q 2025

(in thousands, except per share data - unaudited)

	2025		2024		% Increase/ (Decrease)
	Amount	% Revenue	Amount	% Revenue	
Revenues	\$ 750,809	100.0	\$ 764,066	100.0	(1.7)
Cost of goods sold	245,744	32.7	240,212	31.4	2.3
Gross profit	505,065	67.3	523,854	68.6	(3.6)
Operating expenses					
Sales and marketing	75,166	10.0	84,713	11.1	(11.3)
General and administrative	76,659	10.2	75,261	9.9	1.9
Research and development	56,410	7.5	37,472	4.9	50.5
Total operating expenses	208,235	27.7	197,446	25.8	5.5
Operating income	296,830	39.5	326,408	42.7	(9.1)
Interest expense	9,721	1.3	9,721	1.3	-
Investment in equity securities - unrealized gain	(42)	(0.0)	-	-	100.0
Other income	(16,296)	(2.2)	(17,832)	(2.3)	(8.6)
Income before income taxes	303,447	40.4	334,519	43.8	(9.3)
Income tax expense	83,348	11.1	89,362	11.7	(6.7)
Net income	\$ 220,099	29.3	\$ 245,157	32.1	(10.2)
Net income per common share - diluted	\$ 3.10		\$ 3.48		
Weighted-average common shares outstanding - diluted	70,896		70,364		

Reconciliation of GAAP to Non-GAAP Financial Measures

(in thousands, except per share and percent data – unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2025	2024	2025	2024
Net income	\$ 78,755	\$ 62,073	\$ 151,700	\$ 193,139
Stock and incentive plan compensation	22,321	18,479	43,519	33,863
Amortization of acquired intangible assets	7,971	10,122	15,987	20,053
Campus consolidation costs	7	(5)	67	14
Contingent consideration fair value adjustments	-	100	-	100
Non-recurring fees	155	-	2,633	-
Gain on sale of assets	-	-	-	(6,254)
Strategic collaboration and license costs	10,000	38,191	15,413	66,191
Investment in equity securities - unrealized (gain) loss ^(a)	(14,531)	22,537	331	(38,167)
Acquisition-related costs	22,921	821	27,672	1,609
Other	1,231	679	(3,221)	1,468
Income tax effect of non-GAAP adjustments ^(b)	(18,206)	(26,158)	(34,002)	(26,859)
Adjusted net income	\$ 110,624	\$ 126,839	\$ 220,099	\$ 245,157
Adjusted net income, as a percentage of revenues	29.3%	32.2%	29.3%	32.1%

	Three Months Ended June 30,		Six Months Ended June 30,	
	2025	2024	2025	2024
Net income per share - diluted	\$ 1.12	\$ 0.88	\$ 2.14	\$ 2.74
Stock and incentive plan compensation	0.32	0.26	0.61	0.48
Amortization of acquired intangible assets	0.11	0.14	0.23	0.28
Campus consolidation costs	0.00	(0.00)	0.00	0.00
Contingent consideration fair value adjustments	-	0.00	-	0.00
Non-recurring fees	0.00	-	0.04	-
Gain on sale of assets	-	-	-	(0.09)
Strategic collaboration and license costs	0.14	0.54	0.22	0.94
Investment in equity securities - unrealized (gain) loss ^(a)	(0.21)	0.32	0.00	(0.54)
Acquisition, integration and divestiture-related costs	0.33	0.01	0.39	0.02
Other	0.02	0.01	(0.05)	0.02
Income tax effect of non-GAAP adjustments ^(b)	(0.26)	(0.36)	(0.48)	(0.37)
Adjusted net income per share - diluted ^(c)	\$ 1.57	\$ 1.80	\$ 3.10	\$ 3.48
Weighted-average common shares outstanding - diluted	70,312	70,601	70,896	70,364

(a) Non-GAAP amount excludes a gain of \$42 from the change in value of other assets for the three and six months ended June 30, 2025.

(b) The income tax effect of the adjustments between GAAP net income and adjusted net income (non-GAAP) takes into account the tax treatment and related tax rate that apply to each adjustment in the applicable tax jurisdiction.

(c) Amounts may not add due to rounding.

Consolidated Statement of Operations

(in thousands, except per share data – unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2025	2024	2025	2024
Revenues	\$ 378,045	\$ 394,091	\$ 750,809	\$ 764,066
Cost of goods sold	137,034	138,317	272,098	266,446
Gross profit	241,011	255,774	478,711	497,620
Operating expenses				
Sales and marketing	41,041	45,035	83,544	90,581
General and administrative	66,515	47,409	123,331	95,304
Research and development	45,489	60,601	81,803	108,625
Total operating expenses	153,045	153,045	288,678	294,510
Gain on sale of assets	-	-	-	6,254
Operating income	87,966	102,729	190,033	209,364
Interest expense	4,917	4,862	9,721	9,721
Investment in equity securities - unrealized (gain) loss	(14,573)	22,537	289	(38,167)
Other income	(6,895)	(9,044)	(21,023)	(17,832)
Income before income taxes	104,517	84,374	201,046	255,642
Income tax expense	25,762	22,301	49,346	62,503
Net income	\$ 78,755	\$ 62,073	\$ 151,700	\$ 193,139
Net income per common share:				
Basic	\$ 1.15	\$ 0.89	\$ 2.21	\$ 2.80
Diluted	\$ 1.12	\$ 0.88	\$ 2.14	\$ 2.74
Weighted-average common shares outstanding:				
Basic	68,516	69,356	68,591	69,056
Diluted	70,312	70,601	70,896	70,364

Consolidated Segment Revenues Analysis

(in thousands – unaudited)

	Three Months Ended June 30,			Six Months Ended June 30,		
	2025	2024	% Change	2025	2024	% Change
PYLARIFY	\$ 250,642	\$ 273,255	(8.3)	\$ 508,296	\$ 532,125	(4.5)
Other radiopharmaceutical oncology	-	-	-	-	384	(100.0)
Total radiopharmaceutical oncology	250,642	273,255	(8.3)	508,296	532,509	(4.5)
DEFINITY	83,939	78,100	7.5	163,150	154,664	5.5
TechneLite	24,982	28,186	(11.4)	44,693	49,900	(10.4)
Other precision diagnostics	6,892	5,825	18.3	12,333	11,757	4.9
Total precision diagnostics	115,813	112,111	3.3	220,176	216,321	1.8
Strategic partnerships and other revenue	11,590	8,725	32.8	22,337	15,236	46.6
Total revenues	\$ 378,045	\$ 394,091	(4.1)	\$ 750,809	\$ 764,066	(1.7)

Reconciliation of Free Cash Flow

(in thousands – unaudited)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2025	2024	2025	2024
Net cash provided by operating activities	\$ 87,106	\$ 84,720	\$ 194,669	\$ 211,958
Capital expenditures	(7,961)	(11,175)	(16,679)	(19,448)
Free cash flow	<u>\$ 79,145</u>	<u>\$ 73,545</u>	<u>\$ 177,990</u>	<u>\$ 192,510</u>
Net cash used in investing activities	<u>\$ (232,472)</u>	<u>\$ (45,086)</u>	<u>\$ (296,190)</u>	<u>\$ (151,615)</u>
Net cash (used in) provided by financing activities	<u>\$ (98,413)</u>	<u>\$ 99</u>	<u>\$ (116,632)</u>	<u>\$ (16,746)</u>

Condensed Consolidated Balance Sheet

(in thousands – unaudited)

	June 30, 2025	December 31, 2024
Assets		
Current assets		
Cash and cash equivalents	\$ 695,572	\$ 912,814
Accounts receivable, net	336,579	321,258
Inventory	62,157	68,025
Other current assets	34,093	24,536
Assets held for sale	73,415	-
Total current assets	1,201,816	1,326,633
Investment in equity securities	45,068	39,489
Property, plant and equipment, net	157,726	176,798
Intangibles, net	359,946	161,761
Goodwill	176,869	61,189
Deferred tax assets, net	138,262	170,233
Other long-term assets	36,390	44,237
Total assets	\$ 2,116,077	\$ 1,980,340
Liabilities and stockholders' equity		
Current liabilities		
Current portion of long-term debt and other borrowings	\$ 796	\$ 974
Accounts payable	40,891	34,560
Accrued expenses and other liabilities	208,600	204,992
Liabilities held for sale	29,845	-
Total current liabilities	280,132	240,526
Asset retirement obligations	136	23,344
Long-term debt and other borrowings, net of current portion	566,847	565,279
Other long-term liabilities	102,179	63,180
Total liabilities	949,294	892,329
Total stockholders' equity	1,166,783	1,088,011
Total liabilities and stockholders' equity	\$ 2,116,077	\$ 1,980,340